Shield Therapeutics plc
Shield Therapeutics plc Fundamental Analysis
Shield Therapeutics plc (SHIEF) shows moderate financial fundamentals with a PE ratio of -8.87, profit margin of -34.32%, and ROE of 1.01%. The company generates $0.0B in annual revenue with strong year-over-year growth of 92.46%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 58.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze SHIEF's fundamental strength across five key dimensions:
Efficiency Score
WeakSHIEF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentSHIEF trades at attractive valuation levels.
Growth Score
ExcellentSHIEF delivers strong and consistent growth momentum.
Financial Health Score
ModerateSHIEF shows balanced financial health with some risks.
Profitability Score
WeakSHIEF struggles to sustain strong margins.
Key Financial Metrics
Is SHIEF Expensive or Cheap?
P/E Ratio
SHIEF trades at -8.87 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, SHIEF's PEG of 0.52 indicates potential undervaluation.
Price to Book
The market values Shield Therapeutics plc at -8.88 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -14.73 times EBITDA. This is generally considered low.
How Well Does SHIEF Make Money?
Net Profit Margin
For every $100 in sales, Shield Therapeutics plc keeps $-34.32 as profit after all expenses.
Operating Margin
Core operations generate -19.39 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.01 in profit for every $100 of shareholder equity.
ROA
Shield Therapeutics plc generates $-23.14 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Shield Therapeutics plc generates limited operating cash flow of $-7.03M, signaling weaker underlying cash strength.
Free Cash Flow
Shield Therapeutics plc generates weak or negative free cash flow of $-7.05M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.01 in free cash annually.
FCF Yield
SHIEF converts -5.22% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-8.87
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.52
vs 25 benchmark
P/B Ratio
Price to book value ratio
-8.88
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.06
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-2.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.90
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
1.009
vs 25 benchmark
ROA
Return on assets percentage
-0.23
vs 25 benchmark
ROCE
Return on capital employed
-0.57
vs 25 benchmark
How SHIEF Stacks Against Its Sector Peers
| Metric | SHIEF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -8.87 | 29.02 | Better (Cheaper) |
| ROE | 100.91% | 745.00% | Weak |
| Net Margin | -34.32% | -46183.00% (disorted) | Weak |
| Debt/Equity | -2.00 | 0.35 | Strong (Low Leverage) |
| Current Ratio | 0.90 | 4.52 | Weak Liquidity |
| ROA | -23.14% | -17797.00% (disorted) | Weak |
SHIEF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Shield Therapeutics plc's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
365.99%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
67.84%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
77.07%
Industry Style: Defensive, Growth, Innovation
High Growth